Conclusion: CBA for ISR is safe and effective with favorable long-term outcomes.

Background: Previous studies have found that diffuse-type ISR predicts recurrence of ISR.

Data indicate that the ISR can either promote or suppress tumor development.

Augmenting hepatic ISR may represent a therapeutic approach to treat metabolic disorders.

Intergroup comparisons were used to compare patients with or without ISR.